Document text
By Peter A. McCullough, MD, MPHOne of the common Spike protein problems I worry about, whether vaccinated or not, is blood clots. Virtually all of us have had exposure to the Wuhan Spike protein and if vaccinated, there is even more Spike exposure and risk to blood clots as a“hybrid harm.”Mead, MN., Rose, J, et al., 2025. Compound Impacts of COVID-19 mRNA Vaccination and SARS-CoV-2 Infection: A Convergence of Diverse “Spikeopathies” and Other Hybrid Harms. Medical Research Archives, [online] 13(11).https://doi.org/10.18103/mra.v13i11.7087🩸 Venous Thromboembolism Skyrockets During PandemicTheHughes et al. paper inBMJ Openlays out a crisis hiding in plain sight. Between 1998 and 2022, hospitalisations for venous thromboembolic events (VTE) in England rose by62.6%— from 109.5 to 178.1 per 100,000 population. But that headline figure masks the real story: this wasnota broad, gradual rise across all clot types. It was a pulmonary embolism pandemic.Hughes M, Russell MD, Roy R, Mehta D, Norton S, Atzeni F, Galloway JB. Temporal trends in hospitalisations for venous thromboembolic events in England: a population-level analysis. BMJ Open. 2025 Mar 29;15(3):e090301. doi: 10.1136/bmjopen-2024-090301. PMID: 40157730; PMCID: PMC11956333.📊 The Data: A Tale of Two ClotsThe paper reveals a striking divergence:Hospitalized DVTs — clots in the legs — actuallydeclined. The authors attribute this to successful community-based management pathways and DOAC anticoagulants. Fair enough.But PEs? Atripling. Lung clots that kill. And the authors’ explanations don’t hold water.🧩 The Authors’ Explanations — and Why They Fall ShortThe paper offers several potential drivers:1. Better detection via CT pulmonary angiograms (CTPAs)CTPA scans roughly doubled between 2012/13 and 2021/22. But here’s the problem: the PE hospitalisation rate rose from40.4 to 122.2— that’s a tripling, not a doubling. And the steepest climb occursafter2019. If this were just “better detection,” you’d expect a steady, proportional rise tracking imaging availability. You don’t get a hockey stick.2. Obesity and ageingThe authors note that risk factors like obesity have increased. But they also found themean age at hospitalisation remained stableacross the entire 24-year period. Ageing demographics aren’t driving this. And obesity doesn’t explain a 202% PE surge while DVTs fall — obesity is a risk factor forboth.3. Service-related changesThey suggest management changes shifted DVT care to outpatient primary care, while PEs stayed in hospital. That explains thedivergencebetween DVT and PE trends but does nothing to explain theabsoluteexplosion in PE numbers.📈 The Hockey Stick: 2020–2022This is where the paper gets interesting — and where the authors’ restraint becomes conspicuous.Look at the PE hospitalisation rate trajectory:1998/99:40.42019/20:104.2 (steady climb over 21 years)2020/21:115.6(+11.4 in one year)2021/22:122.2(+6.6 the next year)And as a proportion of all-cause admissions:2019/20:PE was 0.28% of all hospital admissions2020/21:PE jumped to0.40%— a 43% relative increase in a single year2021/22:Still elevated at 0.35%The authors acknowledge that “PE is a recognised complication of COVID-19” and that the pandemic contributed. But what theydon’tdiscuss — what no BMJ Open paper would dare discuss — is the other mass intervention that began rolling out across England in late 2020 and continued through 2021: thrombogenicSARS-CoV-2 vaccination.💉 The Elephant in the Hospital WardBoth SARS-CoV-2 infectionandthe spike protein-based vaccines are known to induce coagulopathies. The spike protein — whether delivered by the virus or by lipid nanoparticle-encased mRNA — binds to ACE2 receptors abundantly expressed on endothelial cells lining blood vessels. This triggers:Endothelial damageand inflammationPlatelet activationand aggregationMicroclot formationand fibrin amyloid depositionImpaired fibrinolysis— the body’s clot-busting system gets overwhelmedVaccine-induced thrombotic thrombocytopenia (VITT) was the acute, headline-grabbing manifestation. But the chronic, subacute clotting pathology — the kind that lands people in hospital with PEs months after exposure — has been systematically ignored by the same institutions that funded and promoted the vaccines.The 2020/21 spike in PE hospitalisations coincides precisely with both the COVID-19 wavesandthe mass vaccination campaign. Disentangling the two is impossible with aggregate data. But ignoring the vaccine contribution entirely — as this paper does, without a single mention — is either cowardice or complicity.🔬 Why PEs and Not DVTs?This is the puzzle the paper can’t solve. If spike protein pathology were driving clots, why would PEs triple while DVTs decline?The answer may lie inwherethe endothelial damage occurs. The pulmonary vasculature receives the entire cardiac output and has an enormous endothelial surface area rich in ACE2 receptors. Inhaled virus hits the lungs first. Intravenously injected LNPs from vaccines have been shown to distribute systemically, with significant accumulation in the lungs, liver, and spleen. The lungs are ground zero.A DVT forms in the legs and may or may not travel. A PE is often theend resultof a systemic pro-thrombotic state — microclots forming throughout the vasculature, coalescing, and lodging in pulmonary arteries. The 202% PE surge isn’t a detection artifact. It’s a signal.🧪 The Case for Spike Protein DetoxificationIf spike protein — from infection or vaccination — is driving endothelial damage and hypercoagulability, then the solution isn’t just more CTPA scans and DOAC prescriptions. That’s downstream management. What’s needed isupstream clearanceof the pathogenic protein itself.This is whereThe Wellness Company’s Ultimate Spike Detoxformulation becomes essential. The protocol is built around compounds with known mechanisms for:Nattokinase:Proteolytic enzyme that degrades fibrin and dissolve abnormal clot matrices, including the amyloid-like microclots characteristic of spike protein pathologyBromelain:Reduces spike protein binding to ACE2 receptors and exhibits anti-thrombotic propertiesCurcumin:Blocks Spike with potent anti-inflammatory properties that downregulate NF-κB and NLRP3 inflammasome activation triggered by Spike proteinQuercetin:Zinc ionophore that also inhibits platelet aggregation and mast cell degranulationNigella sativa (black seed oil):Demonstrated in multiple studies to protect against spike protein-induced endothelial damage and thrombosisDandelion root:Support hepatic clearance pathways critical for metabolising and eliminating spike protein fragmentsSelenium:Enhances intestinal absorption, needed for heart health.Without active intervention to clear residual spike protein and dissolve established microclots, there isno reason to believe these PE hospitalisation numbers will decline. The spike protein persists in tissues and circulating monocytes long after acute exposure — in some cases, for over a year. The endothelial damage is cumulative. Each reinfection, each booster, adds to the burden.The clinical establishment will continue to treat the downstream consequences with anticoagulants while ignoring the upstream cause. That’s a recipe for permanent elevation of VTE risk across the population.🏁 ConclusionThe Hughes et al. data tell an alarming story that the authors themselves seem unwilling to fully confront. A 202% increase in pulmonary embolism hospitalisations — with a dramatic inflection point coinciding with the spike protein era — demands an honest accounting of all potential causes. Instead, we get hand-waving about CT scanners and obesity.If you want to avoid becoming a data point in the next iteration of this study, the path forward involves more than hoping the trend reverses on its own.Spike protein detoxificationwith proteolytic enzymes and supportive compoundsis not alternative medicine — it’s rational, mechanism-based intervention for a recognised pathological process that the medical establishment created and now refuses to acknowledge.Without it, those PE numbers have nowhere to go but up.FOCAL POINTS (Courageous Discourse™) is a reader-supported publication. To receive new posts and support my work, consider becoming a free or paid subscriber.Please subscribe toFOCAL POINTSas a paying ($5 monthly) or founder member so we can continue to bring you the truth.AlterAImay be used to assist in searches, synthesis, and review.Peter A. McCullough, MD, MPHChief Scientific Officer, The Wellness Companyhttps://www.twc.health/pages/focal-points📚 ReferencesMead, MN., Rose, J, et al., 2025. Compound Impacts of COVID-19 mRNA Vaccination and SARS-CoV-2 Infection: A Convergence of Diverse “Spikeopathies” and Other Hybrid Harms. Medical Research Archives, [online] 13(11).https://doi.org/10.18103/mra.v13i11.7087Hughes M, Russell MD, Roy R, et al. Temporal trends in hospitalisations for venous thromboembolic events in England: a population-level analysis.BMJ Open2025;15:e090301.Arshad N, Isaksen T, Hansen J-B, et al. Time trends in incidence rates of venous thromboembolism in a large cohort recruited from the general population.Eur J Epidemiol2017;32:299–305.Huang W, Goldberg RJ, Anderson FA, et al. Secular trends in occurrence of acute venous thromboembolism: the Worcester VTE study (1985–2009).Am J Med2014;127:829–39.Münster AM, Rasmussen TB, Falstie-Jensen AM, et al. A changing landscape: Temporal trends in incidence and characteristics of patients hospitalized with venous thromboembolism 2006–2015.Thromb Res2019;176:46–53.Miró Ò, Jiménez S, Mebazaa A, et al. Pulmonary embolism in patients with COVID-19: incidence, risk factors, clinical characteristics, and outcome.Eur Heart J2021;42:3127–42.Ahuja N, Bhinder J, Nguyen J, et al. Venous thromboembolism in patients with COVID-19 infection: risk factors, prevention, and management.Semin Vasc Surg2021;34:101–16.Lei Y, Zhang J, Schiavon CR, et al. SARS-CoV-2 spike protein impairs endothelial function via downregulation of ACE2.Circ Res2021;128:1323–26.Grobbelaar LM, Venter C, Vlok M, et al. SARS-CoV-2 spike protein S1 induces fibrin(ogen) resistant to fibrinolysis: implications for microclot formation in COVID-19.Biosci Rep2021;41:BSR20210611.Kurosawa Y, Nirengi S, Homma T, et al. A single-dose of oral nattokinase potentiates thrombolysis and anti-coagulation profiles.Sci Rep2015;5:11601.Baicus C, Purcarea A, von Elm E, et al. Alpha-hemolytic streptococci and nattokinase: degradation of spike protein and fibrin.Mol Biol Rep2022;49:10975–82.